Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice
about
The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onsetConverging mechanisms in ALS and FTD: disrupted RNA and protein homeostasisLysosomal storage diseases and the heat shock response: convergences and therapeutic opportunitiesKeep your heart in shape: molecular chaperone networks for treating heart diseaseTherapeutic neuroprotective agents for amyotrophic lateral sclerosisHeat shock transcription factor 1 as a therapeutic target in neurodegenerative diseasesTargeting protein homeostasis in sporadic inclusion body myositis.Molecular chaperone mediated late-stage neuroprotection in the SOD1(G93A) mouse model of amyotrophic lateral sclerosisHeat shock proteins and protection of the nervous systemPutting the heat on ALSCo-induction of the heat shock response ameliorates disease progression in a mouse model of human spinal and bulbar muscular atrophy: implications for therapyHold me tight: Role of the heat shock protein family of chaperones in cardiac diseaseActivation of the heat shock response in a primary cellular model of motoneuron neurodegeneration-evidence for neuroprotective and neurotoxic effectsActivation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70Riluzole increases the amount of latent HSF1 for an amplified heat shock response and cytoprotectionPlasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALSHSF1 protects neurons through a novel trimerization- and HSP-independent mechanismMembrane-lipid therapy in operation: the HSP co-inducer BGP-15 activates stress signal transduction pathways by remodeling plasma membrane raftsRedox proteomics in selected neurodegenerative disorders: from its infancy to future applications.A comprehensive assessment of the SOD1G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis.Heat shock factor 1 regulates lifespan as distinct from disease onset in prion disease.Protein nitration in a mouse model of familial amyotrophic lateral sclerosis: possible multifunctional role in the pathogenesis.Mitochondrial proteomic analysis of a cell line model of familial amyotrophic lateral sclerosis.HSF1-controlled and age-associated chaperone capacity in neurons and muscle cells of C. elegans.To fold or not to fold: modulation and consequences of Hsp90 inhibition.Protein Homeostasis in Amyotrophic Lateral Sclerosis: Therapeutic Opportunities?Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia ContinuumHsp70 expression and induction as a readout for detection of immune modulatory components in food.Altered axonal architecture by removal of the heavily phosphorylated neurofilament tail domains strongly slows superoxide dismutase 1 mutant-mediated ALS.Complex genetics of amyotrophic lateral sclerosis.One universal common endpoint in mouse models of amyotrophic lateral sclerosis.Heat shock protein 90 in neurodegenerative diseasesNonsteroidal anti-inflammatory drugs differentially affect the heat shock response in cultured spinal cord cells.Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease.Hsp70 and its molecular role in nervous system diseasesPotential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis.Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS.The biology of proteostasis in aging and disease.Meta-analysis of heat- and chemically upregulated chaperone genes in plant and human cells.Scolopendra subspinipes mutilans attenuates neuroinflammation in symptomatic hSOD1(G93A) mice.
P2860
Q24650098-9FD69A42-66A4-4D7E-86B8-C4AF42671D7EQ26863439-55E6E181-F374-47B2-9556-1AE1703D7D54Q27004531-527511BD-8998-4944-A113-BF47DE04DEDFQ27010429-026807F9-F8F3-46FC-85B3-A9F675494F80Q27015029-DA8508E7-04F7-4E29-8DB8-791F60386FB3Q27026884-C62C4586-A096-47DC-AD3D-CB3B7D7AEF13Q27324564-1696D1EC-F74D-48F2-8454-73AA6B1D06A5Q28115951-3C821838-980C-4B69-8540-D8F9DEF5A003Q28237891-E6153FAF-EF76-48FE-8E9B-1353AFE9C1ABQ28253971-405D0D25-2EA6-48EB-B743-BE77C368825DQ28285156-8BF28712-96FB-4E19-B137-C08E032E3F32Q28296634-CCFD03D3-D821-41CD-9378-BB6CCBFCF319Q28307965-630FD1D8-0BAC-4DB7-84A9-6AD51DC729ADQ28472376-AF9E757C-4CDB-48D3-8447-4F221F8B41ABQ28473241-02F44BF8-F4D6-4152-A24D-7E2949F02B8FQ28481340-D26859DE-B56C-4049-A6ED-F31C87F3B538Q28582569-FF47E530-4476-41F7-A4D6-3ED62B039350Q28741590-82605E1C-E4C7-454F-8A9D-0CF561F17146Q30446460-254F92F2-E8E5-469F-AD30-FD7B90DDFCB0Q30473769-D8389297-A737-4305-8661-3966BC25F87AQ30483457-3153F1B2-1C33-43A5-90B0-1DC4B6383996Q30777447-73E80F3E-90D8-4ED0-A85A-699FFCE6B467Q33208192-E73E5D13-D309-4848-B307-ED7D3C306712Q33522212-41F9E748-60BB-4BF7-A054-D3143A1E81EAQ33531705-92F64EFA-FAA6-4352-B616-51260A534A16Q33621868-A5CA52AA-A8EE-416C-83EB-31DC126C4AFBQ33653996-E6EA0EA2-883A-4513-920B-3C3D3D557D2CQ33838876-899D6572-1DCB-444A-B608-736EA73800BAQ33900561-FB5EEB16-D367-4467-9B04-E9343816885CQ33910597-B8DD1783-CBE8-41EF-BA81-176B4B208369Q33936763-2B17A522-F53B-491E-B722-59E7D055BB8FQ33961301-699C76BB-884E-4358-B8EE-CDF691CA4E34Q34020316-545EE702-5BA9-4D81-B129-B2F9E0369A27Q34114458-BE0575B2-65E8-42B9-AA98-28E3C17D590CQ34170760-68FA7F70-CCE5-483A-A59E-3D1FC05219D8Q34276055-790F24F8-118B-4D2D-98EC-CBADBFEDD747Q34321059-18467E89-2977-4F51-B0F3-73DF41DC8706Q34467650-6A6D9B2F-BF19-44CC-8FF5-2C713E1C0583Q34505905-56A3DC30-E212-4841-9A4E-6286D360B3FCQ34507926-49A9F2E7-0AAD-49EF-9023-659B9AF776E6
P2860
Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Treatment with arimoclomol, a ...... isease progression in ALS mice
@ast
Treatment with arimoclomol, a ...... isease progression in ALS mice
@en
Treatment with arimoclomol, a ...... isease progression in ALS mice
@nl
type
label
Treatment with arimoclomol, a ...... isease progression in ALS mice
@ast
Treatment with arimoclomol, a ...... isease progression in ALS mice
@en
Treatment with arimoclomol, a ...... isease progression in ALS mice
@nl
prefLabel
Treatment with arimoclomol, a ...... isease progression in ALS mice
@ast
Treatment with arimoclomol, a ...... isease progression in ALS mice
@en
Treatment with arimoclomol, a ...... isease progression in ALS mice
@nl
P2093
P3181
P356
P1433
P1476
Treatment with arimoclomol, a ...... isease progression in ALS mice
@en
P2093
Bernadett Kalmar
Dairin Kieran
James R T Dick
Joanna Riddoch-Contreras
Linda Greensmith
P2888
P3181
P356
10.1038/NM1021
P407
P577
2004-04-01T00:00:00Z